ALK-Abelló A/S (CPH:ALK.B)
263.20
+3.80 (1.46%)
Jun 17, 2026, 4:59 PM CET
ALK-Abelló Employees
ALK-Abelló had 2,759 employees as of March 31, 2026. The number of employees increased by 23 or 0.84% compared to the same quarter last year.
Employees
2,759
Change
23
Growth
0.84%
Revenue / Employee
2.38M DKK
Profits / Employee
463.94K DKK
Market Cap
58.32B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 2,759 | 23 | 0.84% |
| Dec 31, 2025 | 2,613 | -140 | -5.09% |
| Sep 30, 2025 | 2,764 | -31 | -1.11% |
| Jun 30, 2025 | 2,782 | -24 | -0.86% |
| Mar 31, 2025 | 2,736 | -92 | -3.25% |
| Dec 31, 2024 | 2,753 | -71 | -2.51% |
| Sep 30, 2024 | 2,795 | 55 | 2.01% |
| Jun 30, 2024 | 2,806 | 79 | 2.90% |
| Mar 31, 2024 | 2,828 | 116 | 4.28% |
| Dec 31, 2023 | 2,824 | 144 | 5.37% |
| Sep 30, 2023 | 2,740 | 136 | 5.22% |
| Jun 30, 2023 | 2,727 | 140 | 5.41% |
| Mar 31, 2023 | 2,712 | 146 | 5.69% |
| Dec 31, 2022 | 2,680 | 143 | 5.64% |
| Sep 30, 2022 | 2,604 | 124 | 5.00% |
| Jun 30, 2022 | 2,587 | 118 | 4.78% |
| Mar 31, 2022 | 2,566 | 107 | 4.35% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 67,900 |
| Demant | 26,704 |
| Coloplast | 17,083 |
| GN Store Nord | 7,736 |
| Ambu A/S | 5,200 |
| H. Lundbeck | 5,000 |
| Embla Medical | 4,500 |
| Genmab | 3,088 |
ALK-Abelló News
- 2 days ago - EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis - GlobeNewsWire
- 6 days ago - Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap - GlobeNewsWire
- 16 days ago - Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff - GlobeNewsWire
- 21 days ago - ALK-Abello initiated with a Buy at Berenberg - TheFly
- 6 weeks ago - ALK-Abelló Quarterly report: Q1 2026 - Filings
- 6 weeks ago - ALK-Abelló Slides: Q1 2026 - Filings
- 6 weeks ago - ALK-Abelló Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - ALK-Abelló Quarterly report: Q1 2026 - Filings